Shares of biotechnology company Moderna Inc. MRNA fell more than 6% in Wednesday’s regular trading session, but rebounded more than 1% in the extended session.
What Happened: The after-hours surge came as Moderna reported the effectiveness of its COVID-19 vaccine against variants in an internal study.
The biotech company reported that a single booster dose of its COVID-19 vaccine generated promising immune response against the B.1.351 and P.1 novel coronavirus variants first identified in South Africa and Brazil, respectively, citing initial data from a Phase 2 study.
The company noted that the single 50-microgram dose of its vaccine given as a booster to previously vaccinated individuals in the mid-stage trial increased neutralizing antibody responses against the original virus as well as the two variants of concern.
Why It Matters: Moderna’s shares fell sharply in the regular trading session earlier after President Joe Biden's administration voiced support for a proposal to waive patent rights covering COVID-19 vaccines. The loss of patent protection could negatively impact the sales and profits of drugmakers such as Moderna.
Moderna’s COVID-19 vaccine, which requires two doses to be given four weeks apart, received the FDA emergency use authorization in December last year.
Price Action: Moderna’s shares closed 6.2% lower in Wednesday’s regular trading session at $162.84, but added almost 1.1% in the after-hours session to $164.60.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.